Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.12
-3.4%		$1.79
$0.94
▼
$46.50
$8.10M2.85301,608 shs85,371 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.88
+1.1%		$3.98
$1.64
▼
$39.92
$8.24M2.9184,430 shs106,194 shs
Exicure, Inc. stock logo
XCUR
Exicure
$1.41
+12.8%		$1.54
$1.05
▼
$9.48
$8.18M3.6335,988 shs83,697 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-92.10%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-6.45%-23.68%-74.22%-87.52%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
0.00%+10.71%-55.24%-69.04%-94.19%
Exicure, Inc. stock logo
XCUR
Exicure
0.00%-4.58%-7.06%-56.14%-73.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.12
-3.4%		$1.79
$0.94
▼
$46.50
$8.10M2.85301,608 shs85,371 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.88
+1.1%		$3.98
$1.64
▼
$39.92
$8.24M2.9184,430 shs106,194 shs
Exicure, Inc. stock logo
XCUR
Exicure
$1.41
+12.8%		$1.54
$1.05
▼
$9.48
$8.18M3.6335,988 shs83,697 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-92.10%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-6.45%-23.68%-74.22%-87.52%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
0.00%+10.71%-55.24%-69.04%-94.19%
Exicure, Inc. stock logo
XCUR
Exicure
0.00%-4.58%-7.06%-56.14%-73.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
1.50
ReduceN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.50
Moderate Buy$67.505,926.79% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2.20
Hold$64.003,304.26% Upside
Exicure, Inc. stock logo
XCUR
Exicure
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CLSD, SKYE, XCUR, and CODX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/18/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/10/2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/11/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/11/2026
Exicure, Inc. stock logo
XCUR
Exicure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$3.33M0.64N/AN/A($7.68) per share-0.05
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$620K12.61N/AN/A$9.14 per share0.12
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$5.00 per shareN/A
Exicure, Inc. stock logo
XCUR
Exicure
$500K18.47N/AN/A$0.62 per share2.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$5.19N/AN/AN/A-665.19%N/A-124.15%N/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$46.90M-$10.32N/AN/AN/A-6,531.77%-210.99%-174.97%11/5/2026 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$55.92M-$10.16N/AN/AN/AN/A-329.08%-201.79%N/A
Exicure, Inc. stock logo
XCUR
Exicure
-$4.95M-$1.32N/AN/AN/AN/A-237.91%-61.98%11/12/2026 (Estimated)

Latest CLSD, SKYE, XCUR, and CODX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.29-$0.27+$0.02-$2.4550N/AN/A
8/14/2026Q2 2026
Exicure, Inc. stock logo
XCUR
Exicure
-$18.60-$0.18+$18.42-$0.18$1.64 millionN/A
8/13/2026Q2 2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$3.00-$1.46+$1.54-$1.46$0.13 million$0.17 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.87
3.87
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
1.81
1.52
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
0.95
0.95
Exicure, Inc. stock logo
XCUR
Exicure
N/A
0.56
0.56

Institutional Ownership

CompanyInstitutional Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%
Exicure, Inc. stock logo
XCUR
Exicure
42.82%

Insider Ownership

CompanyInsider Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
6.70%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.30%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
6.20%
Exicure, Inc. stock logo
XCUR
Exicure
52.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
305.23 million4.89 millionOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
1006.98 million6.82 millionNo Data
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
114.43 million4.15 millionOptionable
Exicure, Inc. stock logo
XCUR
Exicure
506.55 million3.09 millionNot Optionable

Recent News About These Companies

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics
August 3, 2026  |  quiverquant.comQ
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337599/33289/en/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance.html
Exicure Inc (NASDAQ: XCUR) - Share Price and Research
July 15, 2026  |  intelligentinvestor.com.auI
Exicure Reaches Preliminary Settlement in Derivative Lawsuits
July 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XCUR/pressreleases/1140488/exicure-reaches-preliminary-settlement-in-derivative-lawsuits/
Exicure Announces Board and Committee Changes
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319699/33289/en/exicure-announces-board-and-committee-changes.html
Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
June 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68739298-exicure-inc-exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requirement-399.htm
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
June 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requirement-1036240531
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3310084/33289/en/exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requirement.html
Exicure Regains Nasdaq Compliance After Late Quarterly Filing
June 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exicure-regains-nasdaq-compliance-after-late-quarterly-filing?utm_source=marketbeat.com&utm_medium=referral
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304694/33289/en/exicure-announces-receipt-of-nasdaq-delinquency-notice-and-filing-of-form-10-q.html
Exicure delays quarterly filing, trims quarterly loss
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exicure-delays-quarterly-filing-trims-quarterly-loss?utm_source=marketbeat.com&utm_medium=referral
Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies
April 22, 2026  |  quiverquant.comQ
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3279497/33289/en/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100.html
Exicure Inc.
April 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/xcur/company-people
Exicure Strengthens Leadership With New COO and Director
April 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exicure-strengthens-leadership-with-new-coo-and-director?utm_source=marketbeat.com&utm_medium=referral
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
April 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/02/3267814/33289/en/summary-notice-of-pendency-and-proposed-settlement-of-stockholder-derivative-actions.html
Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing
March 25, 2026  |  quiverquant.comQ
Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing
March 25, 2026  |  quiverquant.comQ
Exicure, Inc. Reports Full Year 2025 Financial Results
March 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/25/3262597/33289/en/exicure-inc-reports-full-year-2025-financial-results.html
Exicure, Inc. Reports Full Year 2025 Financial Results
March 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/25/3262598/33289/en/exicure-inc-reports-full-year-2025-financial-results.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Co-Diagnostics stock logo

Co-Diagnostics NASDAQ:CODX

$1.12 -0.04 (-3.45%)
Closing price 04:00 PM Eastern
Extended Trading
$1.17 +0.05 (+4.46%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$1.88 +0.02 (+1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$1.90 +0.02 (+0.85%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Exicure stock logo

Exicure NASDAQ:XCUR

$1.41 +0.16 (+12.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 +0.01 (+0.71%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas